Obesity Clinical Trial
— ENDORUPOfficial title:
Endocrine Disrupting Environmental Chemicals: From Accumulation to Their Role in the Global "Neuro-endocrine" Epidemic of Obesity and Its Metabolic Consequences
| Verified date | January 2013 |
| Source | University Hospital, Antwerp |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Belgium: Ethics Committee |
| Study type | Observational |
Hormonal disruption is the inappropriate alteration of the hormonal system by chemical
substances that are present in our environment. Some chemical substances are capable of
replicating, enhancing or reducing the production, release, transport or action of natural
hormones. Therefore, they are called hormonal or endocrine disrupters. Some 'classic'
endocrine disrupters such as pesticides and dioxins are considered responsible for
infertility, cancer and thyroid problems. Recently, a number of additional chemical
substances were stipulated to have endocrine disrupting capabilities. The industrial
production of these substances in large quantities has led to an accumulation in our
environment and thus possible negative consequences on human health.
The aim of this study is to investigate the rol of these chemical substances in the
occurence of overweight and obesity.
| Status | Active, not recruiting |
| Enrollment | 203 |
| Est. completion date | July 2013 |
| Est. primary completion date | March 2013 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - adult - Overweight (BMI > 25 kg/m²) or obesity (BMI > 30 kg/²) Exclusion Criteria: - Type 1 diabetes mellitus - psychiatric illness |
Observational Model: Cohort, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| Belgium | University Hospital Antwerp | Edegem | Antwerpen |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Antwerp | Universiteit Antwerpen |
Belgium,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Serum levels of polychlorinated biphenyls | The following PCB congeners are measured (official IUPAC number is given): CB 28 CB 52 CB 74 CB 95 CB 99 CB 101 CB 105 CB 118 CB 149 CB 146 CB 153 CB 138 CB 187 CB 183 CB 128 CB 167 CB 174 CB 177 CB 171 CB 172 CB 156 CB 180 CB 170 CB 199 CB 196/203 CB 194 CB 206 CB 209 |
at the moment of entering a weight loss program | No |
| Primary | Serum levels of hydroxylated metabolites of polychlorinated biphenyls | The following hydroxylated metabolites of polychlorinated biphenyls are measured 4-HO-CB79 4-HO-CB120 3HO-CB118 4HO-CB107 3HO-CB153 4HO-CB146 4HO-CB127 3HO-CB138 4HO-CB130 4HO-CB163 4HO-CB187 4-HO-CB162 4-HO-CB177 3HO-CB180 4HO-CB172 4HO-CB193 4-diMeO-CB202 4-HO-CB208 | at the moment of entering a weight loss program | No |
| Primary | serum levels of organochlorine pesticides | The following organochlorine pesticides are measured: alfa- hexachlorocyclohexane, beta-hexachlorocyclohexane, gamma-hexachlorocyclohexane Hexachlorobenzen Ocychlordane Transnonachlor p-p-dichlorodiphenyltrichloroethane, p,p'-dichlorodiphenyldichloroethylene pp-dichlorodiphenyldichloroethane |
at the moment of entering a weight loss program | No |
| Primary | serum levels of polybrominated diphenyl ethers | The following polybrominated diphenyl ethers (BDE) are measured: BDE 28 BDE 47 BDE 100 BDE 99 BDE 154 BDE 153 BDE 183 | at the moment of entering a weight loss program | No |
| Primary | Urinary levels of pollutants | The pollutants detected in urine comprise of bisphenol A, triclosan, phtalates | at the moment of entering a weight loss program | No |
| Primary | Change in serum levels of polychlorinated biphenyls compared to the levels at the start of the weight loss program | The following PCB congeners are measured (official IUPAC number is given): CB 28 CB 52 CB 74 CB 95 CB 99 CB 101 CB 105 CB 118 CB 149 CB 146 CB 153 CB 138 CB 187 CB 183 CB 128 CB 167 CB 174 CB 177 CB 171 CB 172 CB 156 CB 180 CB 170 CB 199 CB 196/203 CB 194 CB 206 CB 209 |
after 3, 6 and 12 months of weight loss | No |
| Primary | change in serum levels of hydroxylated metabolites of polychlorinated biphenyls compared to the level at the start of the weight loss program | The following hydroxylated metabolites of polychlorinated biphenyls are measured 4-HO-CB79 4-HO-CB120 3HO-CB118 4HO-CB107 3HO-CB153 4HO-CB146 4HO-CB127 3HO-CB138 4HO-CB130 4HO-CB163 4HO-CB187 4-HO-CB162 4-HO-CB177 3HO-CB180 4HO-CB172 4HO-CB193 4-diMeO-CB202 4-HO-CB208 | after 3,6 and 12 months of weigth loss | No |
| Primary | Change in serum levels of organochlorine pesticides compared to the level at the start of the weight loss program | The following organochlorine pesticides are measured: alfa- hexachlorocyclohexane, beta-hexachlorocyclohexane, gamma-hexachlorocyclohexane Hexachlorobenzen Ocychlordane Transnonachlor p-p-dichlorodiphenyltrichloroethane, p,p'-dichlorodiphenyldichloroethylene pp-dichlorodiphenyldichloroethane |
after 3,6 and 12 months of weight loss | No |
| Primary | Change in serum levels of polybrominated diphenyl ethers compared to the level at the start of the weight loss program | The following polybrominated diphenyl ethers (BDE) are measured: BDE 28 BDE 47 BDE 100 BDE 99 BDE 154 BDE 153 BDE 183 | After 3,6 and 12 months of weight loss | No |
| Primary | change in urine levels of pollutants compared to the level at the start of the weight loss program | The pollutants detected in urine comprise of bisphenol A, triclosan, phtalates | after 3,6 and 12 months of weight loss | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |